🔔 OpenAI Launches AI Model for Drug Discovery OpenAI is rolling out an early version of an artificial intelligence (AI) model designed to accelerate drug discovery. Named GPT-Rosalind, the model targets life science research, helping extract insights from vast datasets and translate scientific findings into patient-focused medical applications. OpenAI says the model will initially be available as a research preview to select enterprise customers. Early users include pharmaceutical company Amgen, vaccine manufacturer Moderna, and the nonprofit biomedical research organization Allen Institute. OpenAI, Anthropic, and Google, a subsidiary of Alphabet, are increasingly focusing AI applications on science and healthcare—including aiding new drug development and analyzing individual medical data. (Sina Finance) https://t.co/HJc7X6XaW4
Share
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.